Please use this identifier to cite or link to this item:
|Title:||Outpatient-based therapy of oral fludarabine and subcutaneous alemtuzumab for asian patients with relapsed/refractory chronic lymphocytic leukemia||Authors:||Hwang, W.Y.K.
|Issue Date:||2009||Citation:||Hwang, W.Y.K., Dearden, C., Loh, Y.S.M., Linn, Y.C., Tien, S.L., Teoh, G.K.H., How, G.F., Heng, K.K., Goh, Y.T., Lee, L.H. (2009). Outpatient-based therapy of oral fludarabine and subcutaneous alemtuzumab for asian patients with relapsed/refractory chronic lymphocytic leukemia. Advances in Hematology 2009 : -. ScholarBank@NUS Repository. https://doi.org/10.1155/2009/547582||Abstract:||Background. Intravenous alemtuzumab and fludarabine are effective in combination for the treatment of chronic lymphocytic leukemia (CLL), but require hospital visits for intravenous injection. We performed a pilot study to assess the safety and efficacy of outpatient-based oral fludarabine with subcutaneous alemtuzumab (OFSA) for the treatment of relapsed/refractory CLL. Results. Depending on their response, patients were given two to six 28-day cycles of subcutaneous alemtuzumab 30mg on days 1,3, and 5 and oral fludarabine 40mg/ m2 /day for 5 days. Median patient age was 74. The lymphocyte counts of all five patients fell after the 1st cycle of treatment and reached normal/low levels on completion of 2 to 6 cycles of therapy. Platelet counts and hemoglobin were unaffected. All five patients achieved complete hematological remission, while two attained minimal residual disease negativity on 4-color flow cytometry. Conclusions. Our OFSA regimen was effective in elderly Asian patients with relapsed/refractory CLL, and it should be investigated further. © 2009 William Y. K. Hwang et al.||Source Title:||Advances in Hematology||URI:||http://scholarbank.nus.edu.sg/handle/10635/129913||ISSN:||16879104||DOI:||10.1155/2009/547582|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Dec 5, 2019
checked on Nov 29, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.